Ma, Cynthia X.

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies

Cited by 1,513

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesHER2/EGFR in Cancer Research

Cited by 499

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., et al. (2017) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 193

VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Hamilton, E. P., Ma, C., De Laurentiis, M., Iwata, H., Hurvitz, S. A., Wander, S. A., Danso, M., Lu, D. R., Perkins Smith, J., Liu, Y., et al. (2024) · Future Oncology

Advanced Breast Cancer TherapiesProtein Degradation and Inhibitors

Cited by 116